AbbVie is making a bold $10.9 billion bet on the next "drug king"! AbbVie is acquiring Apogee with a 49% premium, aiming for Sanofi's Dupixent.

Global pharmaceutical giant AbbVie (ABBV.US) announced on Monday that it has reached a final agreement to acquire clinical-stage biotechnology company Apogee Therapeutics (APGE.US) in an all-cash deal worth approximately $10.9 billion, marking AbbVie's largest deal since acquiring Allergan, the manufacturer of Botox, for $63 billion in 2019. Under the terms of the agreement, AbbVie will acquire all issued common stock of Apogee at a cash price of $135.11 per share, with a total equity value of approximately $10.9 billion. This offer represents a premium of approximately 49% over Apogee's closing price of $90.38 on Thursday, June 18. Boosted by this news, Apogee's stock price surged nearly 47% to $132.78 in early trading on Monday, while AbbVie also rose by approximately 4.6%. The transaction has received unanimous approval from both companies' boards of directors and is expected to be officially completed in the third quarter of 2026. Strategic positioning in the post-Humira era The strategic logic behind this transaction is deeply rooted in AbbVie's ongoing product cycle transformation. Humira, the anti-inflammatory drug that held the global "pharma king" title for many years, has seen declining sales since losing patent protection. AbbVie's growth engine in recent years has shifted to two of its own immune disease drugs: Skyrizi and Rinvoq. AbbVie expects Skyrizi to generate sales of approximately $21.6 billion in 2026, and Rinvoq to generate approximately $10.2 billion. Together, these two drugs are expected to contribute over $31 billion in annual revenue, accounting for approximately 44% of AbbVie's total quarterly revenue. However, this growth engine is facing increasing competition. Johnson & Johnson's oral psoriasis drug Icotyde has been approved for market, and Tremfya's indications are expanding, gradually encroaching on Skyrizi's market space. Morgan Stanley analyst Chris Schott expressed concerns about the changing competitive landscape on Wall Street during AbbVie's first-quarter earnings call. It is in this context that AbbVie Chairman and CEO Robert Michael turned his attention to Apogee. In a statement, he said that Apogee's highly differentiated pipeline "perfectly aligns with AbbVie's strategic direction." Citigroup analysts pointed out that, given the Phase II clinical data for zumilokibart, the scarcity of high-quality immunological assets, and the strengthened independent position from the recent $1.3 billion funding from Blackstone, the premium paid by AbbVie was "not excessive." Core asset: Targeting a "long-acting" version of Dupixent antibody Apogee's core pipeline is zumilokibart (code name APG777), a long-acting monoclonal antibody targeting IL-13 primarily used to treat moderate to severe atopic dermatitis (AD, eczema). In March 2026, Apogee announced the 16-week data from Part B of the Phase II clinical trial APEX - 346 adult patients with moderate to severe atopic dermatitis participated in the randomized trial, and all primary and secondary endpoints were met with high statistical significance. The key advantage is the dosing frequency. Current standard biologic therapies for atopic dermatitis usually require dosing every 2 to 4 weeks. However, zumilokibart, with its ultra-long half-life, achieved dosing every 3 or 6 months in the Phase II trial. Jeff Hartness, Chief Business Officer of Apogee, stated at a recent Goldman Sachs Group, Inc. meeting that dosing 2 to 4 times a year compared to Dupixent's 26 times a year would be a "key differentiating factor." Guggenheim Securities analysts doubled their peak sales forecast for zumilokibart to $5.2 billion after the Phase II data was released. AbbVie also stated that Apogee's pipeline assets have "blockbuster potential peak sales." Sanofi and Regeneron face a "precise attack" After the announcement, shares of Paris-based Sanofi fell by 3.5% - the market's reaction itself highlights the issue. Dupixent, developed by Sanofi and Regeneron, is the king in the atopic dermatitis field and is expected to generate global sales exceeding $20 billion by 2025, seen as the next generation "pharma king" that could challenge Humira's historical status. Zumilokibart directly competes with Dupixent - targeting the IL-13 pathway in the same way but offering comparable or even superior efficacy with a lower dosing frequency. Wedbush analyst pointed out that the mid-dose group of zumilokibart "surpassed historical benchmarks of Dupixent and Ebglyss." Apogee also plans to initiate a head-to-head clinical trial in the second half of 2026, directly comparing APG279 (combination therapy with zumilokibart) with Dupixent in atopic dermatitis. For Sanofi, the threat comes not only from efficacy comparisons but also from the timing of market access. Apogee expects to initiate Phase III clinical trials for zumilokibart in the second half of 2026, with Phase III data expected to be read out in 2028 and potential market launch around 2029. This means that Dupixent still has approximately 3 years of market exclusivity - but the patent cliff is also approaching, with biosimilars of Dupixent possibly entering the market as early as 2031. Blackstone's "divine intervention": $13 billion funding raises the acquisition threshold A key background to this transaction is Blackstone Inc.'s injection of up to $1.3 billion in strategic funding to Apogee in May. According to the agreement announced at the time, Blackstone provided up to $800 million in synthetic royalty-backed financing (in exchange for tiered royalties ranging from low to mid-single-digit percentages of zumilokibart's annual global sales for 15 years, with no royalties charged after annual sales exceed $8 billion) and up to $500 million in senior corporate debt facilities. Combined with Apogee's $1.3 billion cash reserve at the time, the company had enough funding to advance zumilokibart's Phase III development and commercialization without equity financing. Blackstone's involvement effectively set a valuation anchor for Apogee - the world's largest alternative asset management company's real money bet on the future value of zumilokibart. Citigroup analysts also explicitly noted in their evaluation of the acquisition that Apogee's recent $1.3 billion financing collaboration with Blackstone "strengthened its independent position." This also means that any potential acquirer would have to pay a premium sufficient to satisfy both Blackstone and Apogee shareholders - $10.9 billion, a 49% premium, is the result of this logic. Financial cost: short-term dilution, long-term bet The financial impact of this transaction will be bitter before being sweet. AbbVie plans to complete this acquisition through debt financing. After deducting Apogee's cash and marketable securities, the deal's actual implied value is approximately $10.1 billion. The company expects that this transaction will dilute adjusted earnings per share by approximately 14 cents in 2026, 46 cents in 2027; starting from 2032, the transaction will begin to enhance adjusted earnings per share. Against the backdrop of the impending patent cliff of blockbuster drugs, large pharmaceutical companies are scrambling to fill pipeline gaps through acquisitions. Founded in 2022, Apogee was acquired for $10.9 billion in just four years - a microcosm of the current valuation logic in the biotech field: the quality of clinical data is more important than revenue scale. BMO Capital Markets analysts pointed out that this acquisition "naturally" fits with AbbVie's existing portfolio of immunology and inflammation products. Citigroup analysts described this as a "significant but logical reinforcement acquisition" rather than a "strategic shift" event, and suggested that AbbVie may still need to further broaden its narrative through another transaction. AbbVie stated that the company remains committed to paying strong and growing dividends and will retain financial flexibility for additional business expansion after completing this acquisition. In terms of the timeline, this is a typical long-term bet. It will take several years to complete the Phase III trial of zumilokibart, with potential market sales as early as 2029, and breakeven expected in 2032. This also reflects AbbVie's management's full confidence in its own commercialization capabilities - with a sales network and physician-patient relationships established through years of deep cultivation in immunology, AbbVie has the ability to maximize the value of a late-stage pipeline asset. AbbVie's $10.9 billion acquisition of Apogee is ultimately a game of timing differences. In the short term, this is a financially "dilutive" and strategically "positioning" transaction - exchanging debt for a Phase III pipeline asset that will not generate revenue for several more years. However, in a longer time frame, this is a precise ambush against Sanofi's Dupixent - with a lower dosing frequency and comparable or superior efficacy data, seizing the next-generation standard treatment position in the atopic dermatitis market during the window when Dupixent faces the threat of biosimilars. For AbbVie under Michael's leadership, this is another seed planted for the next decade of growth following Skyrizi and Rinvoq.